Prevalence and Incidence of Drug-Resistant Temporal Lobe Epilepsy in Qatar.
Epidemiology
Qatar
epilepsy
seizure
temporal lobe
Journal
Journal of central nervous system disease
ISSN: 1179-5735
Titre abrégé: J Cent Nerv Syst Dis
Pays: United States
ID NLM: 101595026
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
07
2019
accepted:
26
04
2020
entrez:
9
7
2020
pubmed:
9
7
2020
medline:
9
7
2020
Statut:
epublish
Résumé
Information on the epidemiology of temporal lobe epilepsy associated with hippocampal sclerosis (TLE-HS) from Qatar and the developing countries is scarce. To acquire knowledge on the incidence and prevalence of drug-resistant TLE-HS in Qatar, we designed this analytical and extrapolative systematic review of the existing literature. We searched the electronic database PubMed from 1947 until April, 2018, using the following search terms in the title: "epilepsy" OR "temporal lobe" OR "hippocampal sclerosis" AND "epidemiology" OR "incidence" OR "prevalence." Relevant original studies, reviews, and their references, were included. We extrapolated from the previous international literature to estimate the epidemiology of drug-resistant TLE-HS in Qatar. The estimated Qatar incidence of epilepsy varies from 50 to 61 per 100 000 persons per year, and the estimated prevalence of epilepsy is 6.54 per 1000 population; the estimated incidence of TLE varies from 9.5 to 11.6 patients per 100 000 population per year and the estimated prevalence of TLE is 1.76 patients per 1000 people, with 4721 patients having TLE in Qatar. Finally, the reviewed studies also helped in making an estimate of the Qatar prevalence of drug-resistant TLE-HS to be between 0.3 and 0.6 cases per 1000 people (804-1609 current patients) and the Qatar incidence of drug-resistant TLE-HS (2.3-4.3 cases per 100 000 people, per year) with 62 to 116 new patients per year. Our study suggests that 804 to 1609 current patients (with 62-116 additional patients per year) in Qatar are suffering from drug-resistant TLE-HS; emphasis should be placed on the surgical aspect of the current Qatar Comprehensive Epilepsy Program.
Sections du résumé
BACKGROUND
BACKGROUND
Information on the epidemiology of temporal lobe epilepsy associated with hippocampal sclerosis (TLE-HS) from Qatar and the developing countries is scarce. To acquire knowledge on the incidence and prevalence of drug-resistant TLE-HS in Qatar, we designed this analytical and extrapolative systematic review of the existing literature.
MATERIAL AND METHODS
METHODS
We searched the electronic database PubMed from 1947 until April, 2018, using the following search terms in the title: "epilepsy" OR "temporal lobe" OR "hippocampal sclerosis" AND "epidemiology" OR "incidence" OR "prevalence." Relevant original studies, reviews, and their references, were included. We extrapolated from the previous international literature to estimate the epidemiology of drug-resistant TLE-HS in Qatar.
RESULTS
RESULTS
The estimated Qatar incidence of epilepsy varies from 50 to 61 per 100 000 persons per year, and the estimated prevalence of epilepsy is 6.54 per 1000 population; the estimated incidence of TLE varies from 9.5 to 11.6 patients per 100 000 population per year and the estimated prevalence of TLE is 1.76 patients per 1000 people, with 4721 patients having TLE in Qatar. Finally, the reviewed studies also helped in making an estimate of the Qatar prevalence of drug-resistant TLE-HS to be between 0.3 and 0.6 cases per 1000 people (804-1609 current patients) and the Qatar incidence of drug-resistant TLE-HS (2.3-4.3 cases per 100 000 people, per year) with 62 to 116 new patients per year.
CONCLUSION
CONCLUSIONS
Our study suggests that 804 to 1609 current patients (with 62-116 additional patients per year) in Qatar are suffering from drug-resistant TLE-HS; emphasis should be placed on the surgical aspect of the current Qatar Comprehensive Epilepsy Program.
Identifiants
pubmed: 32636694
doi: 10.1177/1179573520935031
pii: 10.1177_1179573520935031
pmc: PMC7323268
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1179573520935031Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Neuropsychiatr Dis Treat. 2016 May 12;12:1111-8
pubmed: 27257380
Epilepsia. 2001 Mar;42(3):357-62
pubmed: 11442153
Epilepsia. 1975 Mar;16(1):1-66
pubmed: 804401
Seizure. 2001 Sep;10(6):410-4
pubmed: 11700993
Neurology. 2012 Apr 17;78(16):1200-6
pubmed: 22442428
Can J Neurol Sci. 2000 May;27 Suppl 1:S6-10; discussion S20-1
pubmed: 10830320
Neurology. 1998 Nov;51(5):1256-62
pubmed: 9818842
Neurol Sci. 2016 Nov;37(11):1773-1778
pubmed: 27401807
Neurology. 2017 Jan 17;88(3):296-303
pubmed: 27986877
Epilepsia. 2000;41 Suppl 4:S35-40
pubmed: 10963476
Eur J Neurol. 2014 Jun;21(6):827-34
pubmed: 24313982
Acta Neurol Taiwan. 2012 Sep;21(3):115-24
pubmed: 23196731
Brain Pathol. 2012 May;22(3):402-11
pubmed: 22497612
Rev Neurol (Paris). 2015 Mar;171(3):315-25
pubmed: 25746582
Epilepsia. 2011 Aug;52(8):1393-401
pubmed: 21790546
Epilepsy Res. 2013 Mar;104(1-2):167-74
pubmed: 22981337
World Neurosurg. 2017 Mar;99:662-666
pubmed: 28034810
Epilepsia. 2000;41 Suppl 4:S45-50
pubmed: 10963478
Neurol Sci. 2018 Aug;39(8):1431-1435
pubmed: 29756178
Epileptic Disord. 2010 Mar;12(1):22-37
pubmed: 20207601
J Pak Med Assoc. 2005 Jan;55(1):32-7
pubmed: 15816694
Epilepsy Res Treat. 2012;2012:630853
pubmed: 22957234
Neuroepidemiology. 2012;39(2):131-4
pubmed: 22889740
Clin Neurol Neurosurg. 2016 May;144:91-5
pubmed: 27037863
Epilepsia. 1997 Jun;38(6):716-22
pubmed: 9186255
Epilepsy Res. 2015 Nov;117:133-7
pubmed: 26454046
Seizure. 2012 Apr;21(3):165-8
pubmed: 22130005
Epilepsy Behav. 2015 Jun;47:24-33
pubmed: 26017774
Neurology. 2011 Sep 6;77(10):1005-12
pubmed: 21893672
Lancet. 2011 Oct 15;378(9800):1388-95
pubmed: 22000136
Epilepsy Behav. 2004 Feb;5(1):72-80
pubmed: 14751210
Epilepsia. 2016 May;57(5):757-69
pubmed: 27037674
JAMA. 2012 Mar 7;307(9):922-30
pubmed: 22396514
Epilepsia. 2006 May;47(5):928-33
pubmed: 16686659
Epilepsy Behav. 2016 Oct;63:98-102
pubmed: 27588359
Neurology. 2016 May 24;86(21):1938-44
pubmed: 27164679